Literature DB >> 31771829

Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.

Gisela C Muscia1, Federico J Roldán Pacheco2, Silvia E Asís3, Graciela Y Buldain3, Fernanda M Frank4.   

Abstract

Chagas disease is one of the main neglected diseases in the world, being endemic in 21 countries of Latin America. This disease has become a global health problem due to migration of infected people non-endemic countries. Even though this disease affects millions of people, only two drugs are approved for its treatment, benznidazole and nifurtimox, and both have several limitations. We have previously reported the synthesis and biological activity against T. cruzi of polysubstituted quinolines analogous to natural products. Herein, we present the synthesis of rationally-based novel analogous of this family of compounds. All the evaluated compounds presented trypanocidal activity. Three of them (6, 7 and 10) stand out for their selectivity indexes. Ethyl 2-((4-benzyl-1,4-diazepan-1-yl)methyl)-6-chloro-4-phenylquinoline-3-carboxylate (compound 10) was found to display anti-parasite activity, presenting the highest selectivity index. Apart from controlling in vivo the parasitemia levels, compound 10 was able to prevent tissue inflammation, a key factor to prevent the progression to chronic chagasic cardiomyopathy. The therapeutic effects of compound 10 are promising and suggest a new possibility to treat this disease.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biological activity; Chagas’ disease; Quinoline’s derivatives; Synthetic strategies

Mesh:

Substances:

Year:  2019        PMID: 31771829     DOI: 10.1016/j.ejmech.2019.111877

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  New Amino Naphthoquinone Derivatives as Anti-Trypanosoma cruzi Agents Targeting Trypanothione Reductase.

Authors:  Christian Espinosa-Bustos; Mariana Ortiz Pérez; Alonzo Gonzalez-Gonzalez; Ana María Zarate; Gildardo Rivera; Javier A Belmont-Díaz; Emma Saavedra; Mauricio A Cuellar; Karina Vázquez; Cristian O Salas
Journal:  Pharmaceutics       Date:  2022-05-25       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.